comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists Risk of major adverse events stroke associated treatment with or the dual GIP/GLP-1 receptor agonist for type 2 diabetes: A systematic review and meta-analysis Beyond glycemia: Comparing tirzepatide to

[DOI] [PubMed] [Google Scholar] 122.Beiroa D., et al

Volume values characterize the mean volume of the circular area centered around the foveola, corresponding to the 6 mm ring of the circular grid defined by the Early Treatment Diabetic Retinopathy Study [23]

Topiramate Topiramate is approved for the treatment of epilepsy in children aged 2 years and older, and for migraine prophylaxis in those 12 years and above [18,19,20]

It has also been shown that it can influence the proliferation and survival of cells and has a certain effect on the prognosis of some neoplastic diseases

The authors also establish that GLP-1 agonists increase the risk of adverse gastrointestinal events, including diarrhoea and nausea in children, in line with their known side effects in adults

In some of the large-scale clinical studies evaluating the safety of GLP-1RAs against CV disease, the effect on kidneys was evaluated as a secondary endpoint